GSK Update on FDA Review of Promacta(R) (Eltrombopag) Jun 21, 2008
June 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: ) today announced that the United States Food and Drug Administration has extended the priority review period for PROMACTA(R) (eltrombopag) for the short-term treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura, as they require more time to review the application ... On May 30, the Oncology Drugs Advisory Committee unanimously voted, 16-0, that eltrombopag demonstrated a favorable risk-benefit profile... (PR Newswire)
FDA panel favors Glaxo, Ligand blood drug May 31, 2008
British drugmaker Glaxo and partner Ligand want Promacta approved to treat patients' with chronic idiopathic thrombocytopenic purpura, which causes excessive bruising and bleeding. About 60,000 people in the U.S. have the disease, according to Glaxo. (USA Today)
FDA says Glaxo drug fails to control bleeding May 30, 2008
About 60,000 people in the U.S. have chronic idiopathic thrombocytopenic purpura, an immune system disorder that causes the body to destroy its own platelets, components of blood that help with clotting. In worst-case scenarios, the condition can cause fatal hemorrhaging in the brain. (San Diego Union-Tribune -- Business)
Doctor 'Pay-for-performance' Improves Patient Care, Study Shows Jan 12, 2008
20, 2007) Physicians who treat a blood disorder called idiopathic thrombocytopenic purpura, characterized by easy bruising and excessive bleeding, now have a new tool to help them provide the best care for. (Nov. (Science Daily)
GlaxoSmithKline seeks OK for Promacta bleeding disorder drug Dec 21, 2007
Promacta is an oral platelet growth factor therapy being developed to treat chronic idiopathic thrombocytopenic purpura, or ITP.. ITP is a rare disorder characterized by increased platelet destruction or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding. (Philadelphia Business Journal, PA)
Glaxo files for FDA approval on potential blockbuster drug Dec 21, 2007
Promacta, known generically as eltrombopag, is a treatment for chronic idiopathic thrombocytopenic purpura. Patients with the condition do not create enough platelets in the blood, leading to a lack of clotting and an increased risk of bruising and bleeding. (Raleigh Triangle Business Journal, NC)
Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints Dec 9, 2007
Data Show Romiplostim Increased and Sustained Platelet Counts in Splenectomized Adult Patients with Immune Thrombocytopenic Purpura. ATLANTA--()--Amgen Inc. (NASDAQ:AMGN) today announced results from a randomized, pivotal Phase 3 study that showed romiplostim (AMG 531) increased and sustained platelet counts in splenectomized (spleen removed) adult patients with chronic Immune Thrombocytopenic Purpura (ITP). (BusinessWire)
Ligand Presents Positive LGD-4665 Phase I Clinical Trial Results at the American Society of Hematology Annual Meeting (ASH) Dec 9, 2007
Based on its strong potency, convenience and potential for dosing flexibility, we believe that LGD-4665 could be used as treatment for a wide variety of diseases associated with thrombocytopenia, including hepatitis C, chemotherapy-induced thrombocytopenia (CIT), myelodysplastic syndromes (MDS), idiopathic thrombocytopenic purpura (ITP) and several other cancers and liver diseases. LGD-4665 Study Design. (BusinessWire)
Drug May Help Reverse Clotting Deficiency Nov 30, 2007
The new drug is called eltrombopag, and in one study, patients with the autoimmune disorder idiopathic thrombocytopenic purpura (ITP) were able to use the medication to boost their platelet levels and cut their risk for bleeding. In a second study, patients with hepatitis C (HCV)-related cirrhosis of the liver were able to begin antiviral therapy for their condition after eltrombopag raised their platelet counts. (MEDLINEplus)
Immune Thrombocytopenic Purpura — From Agony to Agonist Nov 29, 2007
In the summer of 1950, two hematology fellows working at the Barnes Hospital in St. Louis William J. Harrington and James W. Hollingsworth hatched a plan to test their idea that the cause of the idiopathic thrombocytopenic purpura (ITP) in a woman under their care was a factor in the blood that destroyed platelets. They decided that of the two fellows, the one whose blood type matched the patient's would receive 500 ml of her blood. (New England Journal of Medicine)
Eltrombopag studied in Idiopathic Thrombocytopenic Purpura Nov 29, 2007
Public release date: 28-Nov-2007. Contact: Andrew Klein. (EurekAlert!)
MS drug called effective, with checks for side effect Oct 15, 2007
Six patients in the trial were diagnosed with idiopathic thrombocytopenic purpura, characterized by a decline in platelet counts that can lead to potentially catastrophic internal bleeding. One patient died, four were successfully treated, and one recovered without treatment. (Boston Globe)
Fairfield County scene: Golfing for a cure Aug 7, 2007
Triathlon Darien Sport Shop and the Idiopathic Thrombocytopenic Purpura Foundation of Darien present the third annual triathlon to raise funds for ITP research. Triathlons will be held in Darien and New Canaan; see Web site for locations. (Stamford Advocate)
Fairfield County scene: Castaways gala Jul 9, 2007
Triathlon Darien Sport Shop and the ITP (Idiopathic Thrombocytopenic Purpura) Foundation of Darien present the third annual triathlon to raise funds for ITP research. Triathlons will be held in Darien and New Canaan; see Web site for locations. (Greenwich Time)
Thrombocytopenia Jul 1, 2007
Immense blood transfusions can weaken platelet concentration in the blood Idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and hemolytic- uremic syndrome (body can use or destroy too many platelets) (1). What drugs are associated with the development of thrombocytopenia and how is thrombocytopenia treated in individuals. (Suite101.com)
Fairfield County Scene Jun 18, 2007
Triathlon Darien Sport Shop and the ITP (Idiopathic Thrombocytopenic Purpura) Foundation of Darien presents the third annual triathlon for athletes to swim 0. 5 miles, bicycle 5 miles and run 5 miles in succession to raise funds for ITP research. (Stamford Advocate)
GlaxoSmithKline Cites Promacta Results Jun 12, 2007
The treatment is aimed at patients with idiopathic thrombocytopenic purpura, a bleeding disorder where blood does not clot properly. Patients with the condition have a low platelet count. (Forbes)
Autoimmune Neutropenia Jun 6, 2007
Similar to the platelet deficiency idiopathic thrombocytopenic purpura, vaccines are suspected of triggering this disorder. Treatment. (Suite101.com)
Multiple Autoimmune Syndrome Apr 11, 2007
Type 3 MAS groups together autoimmune thyroid disease, myasthenia gravis and/or thymoma, Sjogren s syndrome, , idiopathic thrombocytopenic purpura (ITP), , insulin dependent diabetes, vitiligo,, systemic lupus erythematosus (SLE), and dermatitis herpetiformis. For this group, the immune system marker HLA-B8 and/or DR3 or DR5 seems to be an important factor. (Suite101.com)
Clinical Trials Update: March 22, 2007 Mar 23, 2007
Thrombocytopenia and Thrombocytopenia Prevention (Health-Finder)
JEFFERSON AWARDPresented to Mark and Bonnie Barnes Feb 12, 2007
JEFFERSON AWARD / Presented to Mark and Bonnie Barnes / Group salutes soothing skills, spirits of nurses. "Even when Pat was totally sedated, they were amazing. We wanted to find a way to go around the country and say thank you to nurses for the kind of care they give people every day. "With ITP, your body creates antibodies that attack your platelets. (San Francisco Chronicle)
Online tool helps physicians improve care of patients with bleeding disorder Feb 8, 2007
(WASHINGTON and PHILADELPHIA, February 7, 2007) Physicians who treat a blood disorder called idiopathic thrombocytopenic purpura (ITP), characterized by easy bruising and excessive bleeding, now have a new tool to help them provide the best care for patients with this disease. This Web-based performance evaluation tool is the first non-malignant hematology Practice Improvement Module (PIM), co-created by the American Society of Hematology (ASHTM) and the American Board of Internal Medicine... (EurekAlert! -- Business News)
Discovery May Lead To Novel Treatments For Autoimmune And Chronic Inflammatory Diseases Jan 30, 2007
For years, doctors have used IVIG to treat patients with autoimmune and chronic inflammatory diseases, such as dermatomyositis, Kawasaki disease, multiple sclerosis, lupus, chronic lymphocytic leukemia, and idiopathic thrombocytopenic purpura, but just how the therapy works has remained a mystery. Some researchers have shown that IVIG works, in part, by activating a receptor known as Fc3RIIb, which then suppresses auto-antibody-mediated inflammation. (Science Daily)
Positive clinical trial results of investigational thrombocytopenia agent Dec 13, 2006
AkaRx has begun enrolling clinical trial sites and patients into a Phase II study in adult refractory Idiopathic Thrombocytopenic Purpura (ITP). Additional information for the media and clinical investigators rate partners interested in collaborating with AkaRx on thrombocytopenia trials is available on the AkaRx corporate website. (EurekAlert!)
Man arrested over mosh pit death Aug 11, 2006
Korn cancelled their European tour earlier this year after lead singer Jonathan Davis was diagnosed with the rare bleeding disorder ITP (Idiopathic Thrombocytopenic Purpura). The California-based band have sold more than 25m records worldwide. (BBC News -- Entertainment)
Investors put $15M into biotechnology firm Jul 16, 2006
Steven H. Kane, the president and CEO of Protalex (OTCBB: PRTX), said the money will be used to continue developing PRTX-100, the company's flagship product being studied as a potential treatment for idiopathic thrombocytopenic purpura, rheumatoid arthritis and other autoimmune diseases. Related Industry stories. (Philadelphia Business Journal, PA)
News Tip From IG Living Magazine and FFF Enterprises: U.S. IVIG Patients at Risk for Lack of Treatment Jun 27, 2006
IVIG is used to treat primary immune deficiency diseases, neuropathies, myositis, bone marrow transplants, myasthenia gravis, idiopathic thrombocytopenic purpura and other serious immune system disorders. The Medicare Modernization Act of 2003 resulted in a congressionally mandated reduction in Medicare Part B reimbursement rates for IVIG, effective January 1, 2005, and established two rates for administering IVIG to patients, depending on where they receive treatment: in the physician office... (PR Newswire)
GlaxoSmithKline says eltrombopag raises platelet count Jun 20, 2006
Virtual Stock Exchange. The company announced on Sunday the results from a global Phase II study of its investigational small molecule oral platelet growth factor, eltrombopag. (MarketWatch)
Korn Illness Jun 14, 2006
The Korn frontman issued a statement explaining that he is suffering from a blood disorder called Idiopathic thrombocytopenic purpura ... "I was getting very weak after the shows so I saw a doctor in London Friday. He took some blood tests and when the results came in, they rushed me to the hospital. It turned out I have ITP [Idiopathic Thrombocytopenic Purpura]. It's too hard to spell, but basically it's a blood infection where because of an allergic reaction, my blood platelets - the stuff my... (antiMUSIC.com)
Korn singer falls ill, band cancels UK tour Jun 13, 2006
"I started getting these weird bruises all over my body about two weeks ago. I was getting very weak after the shows so I saw a doctor in London on Friday. He took some blood tests and when the results came in they rushed me to [a London-area] hospital."It turned out I have ITP [Idiopathic Thrombocytopenic Purpura. It's too hard to spell, but basically it's a blood infection where because of an allergic reaction, my blood platelets--the stuff my bone marrow produces to help my blood clot--were... (LiveDaily.com)
Canadian Blood Services Scientist Invents Potential Alternative For High-demand Blood Product May 24, 2006
This synthetic could be the stepping stone to replacing IVIg which is used to treat a variety of conditions, including ITP (idiopathic thrombocytopenic purpura), a disease that can cause uncontrolled bleeding, and sometimes even death. As will be published in the June edition of the scientific journal Nature Medicine, Lazarus' research team has made great strides in determining how IVIg works, a major milestone in the study of this product. (Science Daily)
Clinical Trials Update: Jan. 19, 2006 (HealthDay) Jan 20, 2006
Clinical Trials Update: Jan. 19, 2006 - Yahoo. Secondary Navigation. (RSS - Yahoo News - Health)
